Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (immunoglobulin G \[IgG\] inhalation solution) compared with placebo over a period of 6 to 12 months independent of the occurrence of pulmonary exacerbations. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the TTF exacerbation.

NCT Number	NCT07048262
Lead Sponsor	CSL Behring
Conditions	Non-cystic Fibrosis Bronchiectasis
Enrollment	450 participants
Start Date	2025-09-03
Primary Completion	2028-02-28 (estimated)
Study Completion	2028-03-28 (estimated)
Updated on ClinicalTrials.gov	2025-11-10